Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)

Randall, LM; O'Malley, DM; Monk, BJ; Coleman, RL; Gaillard, S; Adams, S; Duska, LR; Dalton, H; Holloway, RW; Huang, M; Chon, HS; Cloven, NG; Elnaggar, AC; O'Cearbhaill, RE; Waggoner, S; Tarkar, A; Striha, A; Nelsen, LM; Baines, A; Samnotra, V; Konstantinopoulos, PA

Randall, LM (通讯作者)，Massey Canc Ctr, 1001 E Leigh St, Richmond, VA 23298 USA.

GYNECOLOGIC ONCOLOGY, 2023; 178 (): 161

Abstract

Objective. This study assessed the efficacy, safety, and health-related quality of life (HRQoL) of the treatment regimen of dostarlimab, a programmed ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索